Translate

Monday, January 27, 2020

thumbnail

MNKD MannKind Corp. gains 22% Jan 27, 2020

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is based in Valencia, California.http://www.priceseries.com/trade/MNKD-MannKind-Corp-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2020010620200127.html

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive